Pharmacogenetics of antidepressant response and remission
This collaboratively funded project involves collaborations with national and international investigators working in the filed of antidepressant pharmacogenetics. Since 2013, we have been leading and/or supervising analyses aimed at identifying genetic markers for antidepressant mediated symptom response and remission. We currently co-lead analyses related to the pharmacogenetics of escitalopram with Prof Tianmei Si (Director, Department of Clinical Pharmacology, Peking University) as well as analyses to identify pharmacogenetic markers of desvenlafaxine and venlafaxine with A/Prof Ajeet Singh at Deakin University. Over the next two years, we will specifically be focusing on analyses of genes and variants with functional effects on the integrity of the blood-brain barrier such as ABCB1, which encodes p-glycoprotien, as we have previously shown an association between genetic variation in this gene and antidepressant response.
Singh, A.B.S, Bousman, C.A., Ng, C.H., Byron, K., Berk, M. ABCB1 Polymorphism Predicts Escitalopram Dose Needed for Remission in Major Depression. Translational Psychiatry 2012, 2, e198
Singh, A.B.S, Bousman, C.A., Ng, C.H., Byron, K., Berk, M. Psychomotor depressive symptoms may differentially respond to venlafaxine. International Clinical Psychopharmacology 2013, 28(3): 121-126.
Ng, C., Sarris, J., Singh, A., Bousman, C.A., Byron, K., Peh, L.H., Tan, C.H., Smith, D.J., Schweitzer, I. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Human Psychopharmacology 2013, 28(5): 516-22.
Singh, A.B., Bousman, C.A., Ng, C.H., Berk, M. Antidepressant pharmacogenetics. Current Opinion in Psychiatry 2014, 27(1): 43-51.
Bousman, C.A., Sarris, J., Won, ES., Chang, HS., Singh, A., Lee, HY., Ham, BJ., Tan, CH., Lee, MS., Ng, CH. Escitalopram efficacy in depression: A cross-ethnicity examination of the serotonin transporter promoter polymorphism. Journal of Clinical Psychopharmacology 2014, 34(5): 645-8.
Singh, A.B., Bousman, C.A., Ng, C.H., Berk, M. Effects of persisting emotional impact from child abuse and norepinephrine transporter genetic variation on antidepressant efficacy in major depression: A pilot study. Clinical Psychopharmacology and Neuroscience 2015, 13(1): 53-61.
Bousman, C.A., Katalinic, N., Martin, D.M., Smith, D.J., Ingram, A., Dowling, N., Ng, C., Loo, C.K. Effects of COMT, DRD2, BDNF, and APOE genotypic variation on treatment efficacy and cognitive side-effects of electroconvulsive therapy. Journal of ECT 2015, I31(2): 129-35.
Su YA, Li JT, Dai WJ, Liao XM, Dong LC, Lu TL, Bousman CA*; Si T*.. Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8-weeks of escitalopram treatment. International Clinical Psychopharmacology, Epub 7-Jan-2016.